Maegim한국어

SK바이오사이언스

302440KOSPISector: Pharma & Biotech
₩33,000 2.80%Market cap ₩2.59TAs of Jul 21, 2026 close · updated once daily
B
Grade B53 ptsTop 48% of 2,523 stocks
Financial strength
54.6
Growth momentum
58.3
Price attractiveness
47.4

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

54.6
How much debt does it carry relative to equity?
Debt-to-equity ratio
45.1%
Above median · Top 44.1% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
382.0%
Above median · Top 30.7% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-19.0%
Below median · Top 59.5% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-3.2%
Above median · Top 47.4% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

2

Growth momentum

58.3
How much did revenue grow in a year?
Revenue growth (YoY)
143.5%
Above median · Top 6.2% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
12.6%
Above median · Top 25% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
10.8%
Above median · Top 44.9% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-207.4%
Below median · Top 90.6% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

47.4
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 53.9% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
1.45x
Below median · Top 51.4% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15